What were Johnson & Johnson's key financial results for the quarter ending June 29, 1996?

The provided excerpt does not contain specific financial figures like revenue, net income, or EPS. Investors would need to access the full 10-Q filing (specifically the .txt or detailed HTML versions) to find these crucial financial metrics and understand the company's performance during the quarter.

What business segments does Johnson & Johnson operate in, and how did they perform in this quarter?

While the excerpt mentions the filing pertains to Johnson & Johnson, it does not detail the company's operating segments or their performance. The complete 10-Q would typically break down revenues and profitability by segment, such as Pharmaceuticals, Medical Devices & Diagnostics, and Consumer Health.

Where can I find the complete financial data for Johnson & Johnson's Q2 1996 report?

The complete financial data is contained within the full 10-Q filing accessible through the SEC's EDGAR database. The excerpt shows links to index and text files (e.g., '-96-000003.txt') which would host the detailed financial statements and management discussion.

Are there any significant business developments or risks mentioned in this filing?

The provided directory listing does not offer details on business developments or risk factors. These critical qualitative and quantitative insights are typically found in the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section of the full 10-Q report.

JNJ 10-Q Quarterly Report Q2 FY1996 — Revenue, Net Income, EPS

Summary

Johnson & Johnson (JNJ) reported its quarterly results for the period ending June 29, 1996, in a filing on August 8, 1996. While specific financial figures such as revenue, net income, and earnings per share are not directly detailed in the provided excerpt, the filing indicates the company is adhering to its reporting obligations. Investors should look to the full 10-Q filing for comprehensive financial data, including segment performance, balance sheet information, and cash flow statements. This report serves as a snapshot of JNJ's financial health during the second quarter of 1996. Key areas to examine in the complete filing would include trends in sales across its diversified product segments (e.g., pharmaceuticals, medical devices, and consumer health), any significant changes in operating expenses, and the company's liquidity and capital structure. Understanding these elements is crucial for assessing the company's operational efficiency and its ability to generate shareholder value.

Key Highlights

1Johnson & Johnson (JNJ) filed its 10-Q Quarterly Report for the period ending June 29, 1996.
2The filing was officially submitted on August 8, 1996.
3The provided excerpt is from the SEC's EDGAR database, indicating a standard regulatory disclosure.
4The report is structured within a directory listing typical of SEC filings, containing index and text files.
5Investors rely on these filings for up-to-date financial performance and operational insights.
6Key financial statements such as the Consolidated Statements of Income, Financial Position, and Cash Flows would be detailed within the full 10-Q.

JOHNSON & JOHNSON Quarterly Report for Q2 Ended Jun 30, 1996

Summary

Key Highlights

Frequently Asked Questions